Evidence map›Paper›PMID 36708585›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2023

Association of two ARID5B gene variant single nucleotide polymorphisms with acute lymphoblastic leukemia in the Egyptian population.

Marwa Ahmed Gamaleldin, Salma Alaa Eldin Imbaby

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Marwa Ahmed GamaleldinClinical Pathology, Faculty of Medicine, University of Alexandria, Egypt.ORCID 0000-0002-1622-0054
Salma Alaa Eldin ImbabyClinical Pathology, Faculty of Medicine, University of Alexandria, Egypt.ORCID 0000-0002-8720-3913
Alexandria University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundARID5B SNPs have been linked to ALL in many research studies in which it was identified as a risk factor. From this context, we had great interest to investigate the relationship between ARID5B rs4948488 and ARID5B rs2893881 genotypes and ALL susceptibility and relapse in this study. MATERIALS AND

methodsPeripheral blood mononuclear cells were analyzed for ARID5B rs4948488 and rs2893881 gene polymorphisms by real-time quantitative polymerase chain reaction in 80 ALL patients and 80 controls.

resultsOur results showed that the C/C genotype of ARID5B rs4948488 and A/G genotype and G-allele of rs2893881 were linked to higher ALL incidence. Regarding the relapse of ALL, rs4948488 C/C genotype and C-alleles were significantly associated with relapse of ALL. Meanwhile, rs4948488 C/C genotype and rs2893881 A/A genotype and A-allele are associated with T-ALL, while rs2893881 A/G genotype and G-allele are associated with B-ALL.

conclusionThe results of our study suggested that ARID5B rs4948488 and rs2893881 SNPs might be used risk factors for genetic susceptibility for B-ALL and T-ALL, and that ARID5B s4948488 is related to relapse in ALL patients.<br />.

Indexed as

Precursor Cell Lymphoblastic Leukemia-LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaAllelesCase-Control StudiesDNA-Binding ProteinsEgyptGenetic Predisposition to DiseaseGenotypeHumansLeukocytes, MononuclearPolymorphism, Single NucleotideTranscription FactorsARID5B protein, humanDNA-Binding ProteinsTranscription FactorsAcute Lymphoblastic LeukemiaARID5BGenotypingSNPs

Identifiers

PMID36708585
PMCPMC10152858
OpenAlexW4318387349

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.